Vyloy, a CLDN18.2-directed antibody, is approved for HER2-negative gastric or GEJ adenocarcinoma with CLDN18.2-positive tumors. The Ventana CLDN18 (43-14A) RxDx Assay identifies patients eligible for ...
SANTA CLARA, Calif., April 17, 2025--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the ...
A new retrospective study assessed survival rates in a cohort of patients with early-stage GEJ adenocarcinoma who were treated with either esophagectomy or gastrectomy. Esophagectomy, which was ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in ...
VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive In the SPOTLIGHT ...
Elevation Oncology discontinues EO-3021 development due to insufficient efficacy in phase 1 trial, despite favorable safety profile. EO-3021 trial showed a 22.2% objective response rate and 72.2% ...
A regulatory decision is expected during the fourth quarter of 2025. The Food and Drug Administration (FDA) has granted Priority Review to durvalumab for the treatment of patients with resectable, ...
When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo. The conversion to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback